2BBBullish & Bearish
QuidelOrtho Corporation (QDEL) trades on NASDAQ. It operates in the Health Care sector, Medical Devices industry. Its current 2BB score is 48 out of 100.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. On May 8, 2020 the U.S. Food and Drug Administration issued to Quidel the first emergency use authorization for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs.
QuidelOrtho Corporation’s current 2BB score is 48 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 52 | Moderate |
| Momentum | 50 | Stable |
| Financial strength | 17 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 46 | Moderate |
| CEO | Douglas C Bryant |
| Headquarters | San Diego, California, United States |
| Founded | 1979 |
| Employees | 6.5K |
| 52-week range | $9.92 – $35.58 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-09 | — | 0.4804 | — | $678.90M |
| 2026-11-03 | — | 0.2066 | — | $640.70M |
| 2026-08-06 | — | -0.0364 | — | $632.02M |
| 2026-05-05 | -0.04 | 0.4029 | $619.80M | $686.56M |